Could this be the moment that drug manufacturing takes off in orbit?

Key Points:

• NASA has facilitated decades of research on the effects of microgravity on drug development, with significant advancements occurring after the International Space Station became fully operational in the 2010s, including improved crystalline drug forms like Keytruda.
• Varda Space Industries is pioneering the commercial production of pharmaceuticals in microgravity using autonomous bioreactor-equipped capsules launched since mid-2023, aiming to leverage microgravity’s unique effects on drug crystallization and stability.
• Varda recently announced a collaboration with United Therapeutics Corporation to develop enhanced treatments for rare lung diseases by exploiting microgravity’s influence on therapeutic compound properties, marking a milestone as a publicly traded company invests its own capital in space-based drug production.
• Advances such as reusable rockets and increased capital for space startups have reduced costs and increased launch frequency, enabling Varda to conduct extensive ground-based screening before sending promising pharmaceutical candidates to space for processing.
• Varda’s long-term vision is to become a pharmaceutical company operating in space, producing high-value materials to return to Earth, with plans to increase launch cadence and scale its internal pharmaceutical business alongside its reentry system capabilities.